Pipoxolan inhibits CL1-5 lung cancer cells migration and invasion through inhibition of MMP-9 and MMP-2

Chemico-Biological Interactions

Volumn 236, Issue , 2015, Pages 19-30

  Lee, Min Min ^a   Chen, Ying Yi ^b   Liu, Pei Yi ^b,c   Hsu, Stephen ^b   Sheu, Ming Jyh ^b  

^a ASIA UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

CL1 5 Migration; JNK1 2 p38; Matrix metalloproteinase; Pipoxolan

Indexed keywords

ANTIMETASTATIC AGENT; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE P38; PIPOXOLAN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; 1,3 DIOXOLANE DERIVATIVE; MATRIX METALLOPROTEINASE INHIBITOR;

A549 CELL LINE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CL1-0 CELL LINE; CL1-5 CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; LUNG CANCER CELL LINE; METASTASIS INHIBITION; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; HUMAN; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DIOXOLANES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION;

EID: 84928880634     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2015.04.012     Document Type: Article

References (38)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics CA Cancer J. Clin. 63 2013 2013 11 30
2. C.J. Chiang, Y.C. Chen, C.J. Chen, S.L. You, M.S. Lai, and F. Taiwan Cancer registry task, cancer trends in Taiwan Jpn. J. Clin. Oncol. 40 2010 897 904
3. G.P. Gupta, and J. Massague Cancer metastasis: building a framework Cell 127 2006 679 695
4. M.R. Emmert-Buck, M.J. Roth, Z. Zhuang, E. Campo, J. Rozhin, B.F. Sloane, L.A. Liotta, and W.G. Stetler-Stevenson Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples Am. J. Pathol. 145 1994 1285 1290
5. R. Fridman, M. Toth, D. Pena, and S. Mobashery Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2) Cancer Res. 55 1995 2548 2555
6. L.J. McCawley, and L.M. Matrisian Matrix metalloproteinases: multifunctional contributors to tumor progression Mol. Med. Today 6 2000 149 156
7. O.R. Mook, W.M. Frederiks, and C.J. Van Noorden The role of gelatinases in colorectal cancer progression and metastasis Biochim. Biophys. Acta 1705 2004 69 89
8. Y.W. Chu, P.C. Yang, S.C. Yang, Y.C. Shyu, M.J. Hendrix, R. Wu, and C.W. Wu Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line Am. J. Respir. Cell Mol. Biol. 17 1997 353 360
9. Y.C. Liu, H.Y. Yen, C.Y. Chen, C.H. Chen, P.F. Cheng, Y.H. Juan, C.H. Chen, K.H. Khoo, C.J. Yu, P.C. Yang, T.L. Hsu, and C.H. Wong Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells Proc. Natl. Acad. Sci. U.S.A. 108 2011 11332 11337
10. W.S.M. Pailer, F. Takacs, and K. Mörsdorf Derivate des 1,3-Dioxolan-4-ons und des 1,3-Oxathiolan-5-ons Monatsh. Chem./Chem. Mon. 99 1968 891 901
11. K. Chlud Clinical experiences with a new spasmolytic, Rowapraxin Med. Welt. 33 1969 1801 1803
12. T.Y. Terasoma K Analgesic effect of Rowapraxin (BR-18) in urological diseases Hinyokika Kiyo 17 1971
13. Y.H. Chou, Y.S. Ho, C.C. Wu, C.Y. Chai, S.C. Chen, C.H. Lee, P.S. Tsai, and C.H. Wu Tubulozole-induced G2/M cell cycle arrest in human colon cancer cells through formation of microtubule polymerization mediated by ERK1/2 and Chk1 kinase activation Food Chem. Toxicol. 45 2007 1356 1367
14. B. Przybojewska, E. Dziubaltowska, and Z. Kowalski Genotoxic effects of dioxolane and trioxane in mice evaluated by the micronucleus test Toxicol. Lett. 21 1984 349 352
15. M.J. Sheu, P.Y. Chou, C.S. Huang, I.C. Tsai, Y.C. Chien, S.Y. Lin, H.Y. Tsai, H.C. Cheng, and C.H. Wu Pipoxolan inhibits proliferation of HL-60 human leukaemia cancer cells by arresting the cell cycle at the G0/G1 phase Clin. Exp. Pharmacol. Physiol. 37 2010 605 612
16. Y.Y. Chen, P.Y. Chou, Y.C. Chien, C.H. Wu, T.S. Wu, and M.J. Sheu Ethanol extracts of fruiting bodies of Antrodia cinnamomea exhibit anti-migration action in human adenocarcinoma CL1-0 cells through the MAPK and PI3K/AKT signaling pathways Phytomedicine 19 2012 768 778
17. Y.Y. Chen, L.F. Liu, P.Y. Chou, Y.C. Chien, W.S. Chang, G.J. Huang, C.H. Wu, and M.J. Sheu Ethanol extracts of fruiting bodies of Antrodia cinnamomea suppress CL1-5 human lung adenocarcinoma cells migration by inhibiting matrix metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt signaling pathways Evid. Based Complement Alternat. Med. 2012
18. P.C. Li, C.H. Pan, M.J. Sheu, C.C. Wu, W.F. Ma, and C.H. Wu Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: an in vitro and in vivo study PLoS ONE 9 2014 e96927
19. M.J. Sheu, H.Y. Lin, Y.H. Yang, C.J. Chou, Y.C. Chien, T.S. Wu, and C.H. Wu Demethoxycurcumin, a major active curcuminoid from Curcuma longa, suppresses balloon injury induced vascular smooth muscle cell migration and neointima formation: an in vitro and in vivo study Mol. Nutr. Food Res. 57 2013 1586 1597
20. C.H. Pan, W.H. Lin, Y.C. Chien, F.C. Liu, M.J. Sheu, Y.H. Kuo, and C.H. Wu K20E, an oxidative-coupling compound of methyl caffeate, exhibits anti-angiogenic activities through down-regulations of VEGF and VEGF receptor-2 Toxicol. Appl. Pharmacol. 282 2015 215 226
21. H.A. Omar, S.A. Arafa el, S.A. Salama, H.H. Arab, C.H. Wu, and J.R. Weng OSU-A9 inhibits angiogenesis in human umbilical vein endothelial cells via disrupting Akt-NF-kappaB and MAPK signaling pathways Toxicol. Appl. Pharmacol. 272 2013 616 624
22. J.S. Jung, K. Jung, D.H. Kim, and H.S. Kim Selective inhibition of MMP-9 gene expression by mangiferin in PMA-stimulated human astroglioma cells: involvement of PI3K/Akt and MAPK signaling pathways Pharmacol. Res. 66 2012 95 103
23. Y.F. Chen, J.S. Yang, W.W. Huang, and H.Y. Tsai Novel anti-leukemia activities of pipoxolan operate via the mitochondria-related pathway in human leukemia U937 cells and attenuate U937 cell growth in an animal model Mol. Med. Rep. 3 2010 851 856
24. Y.F. Chen, H.Y. Tsai, K.J. Wu, L.R. Siao, and W.G. Wood Pipoxolan ameliorates cerebral ischemia via inhibition of neuronal apoptosis and intimal hyperplasia through attenuation of VSMC migration and modulation of matrix metalloproteinase-2/9 and Ras/MEK/ERK signaling pathways PLoS ONE 8 2013 e75654
25. F. Animati, M. Berettoni, M. Bigioni, M. Binaschi, A. Cipollone, C. Irrissuto, F. Nardelli, and L. Olivieri Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety Bioorg. Med. Chem. Lett. 22 2012 5013 5017
26. M. Venkatesh, H. Wang, J. Cayer, M. Leroux, D. Salvail, B. Das, J.E. Wrobel, and S. Mani In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation Mol. Pharmacol. 80 2011 124 135
27. A.F. Chambers, and L.M. Matrisian Changing views of the role of matrix metalloproteinases in metastasis J. Natl Cancer Inst. 89 1997 1260 1270
28. P. Iniesta, A. Moran, C. De Juan, A. Gomez, F. Hernando, C. Garcia-Aranda, C. Frias, A. Diaz-Lopez, F.J. Rodriguez-Jimenez, J.L. Balibrea, and M. Benito Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer Oncol. Rep. 17 2007 217 223
29. S. Zucker, R.M. Lysik, M.H. Zarrabi, and U. Moll M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer Cancer Res. 53 1993 140 146
30. S. Ried, C. Jager, M. Jeffers, G.F. Vande Woude, H. Graeff, M. Schmitt, and E. Lengyel Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor J. Biol. Chem. 274 1999 16377 16386
31. E. Lengyel, E. Stepp, R. Gum, and D. Boyd Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras J. Biol. Chem. 270 1995 23007 23012
32. J.A. Aguirre Ghiso, D.F. Alonso, E.F. Farias, D.E. Gomez, and E.B. de Kier Joffe Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype Eur. J. Biochem. 263 1999 295 304
33. P.N. Chen, Y.S. Hsieh, H.L. Chiou, and S.C. Chu Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways Chem. Biol. Interact. 156 2005 141 150
34. J. Westermarck, and V.M. Kähäri Regulation of matrix metalloproteinase expression in tumor invasion FASEB J. 13 1999 781 792
35. K.B. Reddy, S.M. Nabha, and N. Atanaskova Role of MAP Kinase in tumor progression and invasion Cancer Metastasis Rev. 22 2003 395 403
36. K.S. Kumar, B.J. Petersen, L. Khandrika, J.S. Hwa, R.B. Meacham, S. Wilson, and H.K. Koul p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity Cancer Res. 70 2010 832 841
37. E.F. Wagner, and A.R. Nebreda Signal integration by JNK and p38 MAPK pathways in cancer development Nat. Rev. Cancer 9 2009 537 549
38. M. Loesch, H.Y. Zhi, S.W. Hou, X.M. Qi, R.S. Li, Z. Basir, T. Iftner, A. Cuenda, and G. Chen P38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9 J. Biol. Chem. 285 2010 15149 15158